{
    "info": {
        "nct_id": "NCT05797246",
        "official_title": "A Phase II Study of Bevacizumab in Adults With Recurrent Respiratory Papillomatosis (RRP)",
        "inclusion_criteria": "* INCLUSION CRITERIA:\n* Age >= 18 years old.\n* Histologically confirmed diagnosis of RRP.\n* Participants must require procedure(s) to remove papillomatous disease per standard of care.\n* A history of 2 or more surgeries within 12 months prior to treatment initiation in order to control laryngeal and/or tracheal RRP (not required for re-treatment).\n* At least one of the following:\n\n  * A Derkay score of 8 or greater\n  * Measurable disease per RECIST 1.1 (participants with pulmonary RRP only)\n  * Tracheal involvement with RRP that has required two or more clinical interventions in the last 12 months (two or more clinical interventions not required for re-treatment)\n  * Tracheostomy.\n* ECOG performance status of 0-1.\n* Participants must have adequate organ and marrow function as defined below:\n\n  * White blood cells (WBC): >2,000/microL\n  * Absolute neutrophil count (ANC): >=1,500/microL\n  * Hemoglobin: >9.0 g/dL\n  * Platelets: >=100,000/microL\n  * Total bilirubin: <=1.5 mg/dL, except in participants with Gilbert s Syndrome who must have a total bilirubin less than 3.0 mg/dL\n  * Aspartate aminotransferase (AST) /Alanine aminotransferase (ALT): <=2.5 X institutional upper limit of normal (ULN)\n  * Creatinine: within normal institutional limits\n\nOR\n\nCreatinine Clearance (CrCl): >=60 mL/min/1.73 m^2 for participants with creatinine levels above institutional normal (calculated using the Cockcroft-Gault formula).\n\n* Prothrombin time (PT) /International normalized ratio (INR) and Partial thromboplastin time (PTT): <=1 X institutional ULN. In participants on anticoagulation, coagulation tests should be within a therapeutic range.\n* Urinalysis: Urine dipstick < 2+ proteinuria. In participants with >=2+ proteinuria on dipstick urinalysis should undergo a 24-hour urine collection and must demonstrate <=1g of protein in 24 hours to be eligible\n\n  * Participants must have received their last systemic therapy for RRP > 4 weeks or 5 half-lives, whichever is longer, prior to treatment initiation, except for systemic bevacizumab which must be > 1 year prior to treatment initiation (not applicable for re-treatment)\n  * Individuals able to become pregnant and their partners must agree to use highly effective method of contraception (hormonal, intrauterine device (IUD), surgical sterilization ) for the duration of bevacizumab treatment and up to 6 months after completion of bevacizumab treatment. Note: abstinence, defined as no heterosexual sexual intercourse when this is in line with the preferred and usual lifestyle of the participant is also acceptable.\n  * Breastfeeding participants must be willing to discontinue breastfeeding from study treatment initiation through 6 months after bevacizumab treatment discontinuation.\n  * All participants must have the ability to understand and willingness to sign a written informed consent.\n  * All participants must be willing to undergo mandatory biopsy during the study.\n\nEXCLUSION CRITERIA:\n\n-History of significant (i.e., active) cardiovascular disease or thromboembolic event:\n\ncerebral vascular accident/stroke (within 6 months prior to treatment initiation), myocardial infarction (within 6 months prior to treatment initiation), unstable angina, congestive heart failure (>= New York Heart Association Classification Class II), or serious cardiac arrhythmia requiring medication as assessed by EKG.\n\n* History of abdominal fistula or gastrointestinal perforation within 6 months prior to treatment initiation.\n* Major surgery within 4 weeks prior to treatment initiation.\n* Non-healing wound, active ulcer, or untreated bone fracture.\n* History of hemoptysis (>2.5 mL of bright red blood per episode) within 1 month prior to treatment initiation.\n* Evidence of bleeding diathesis or significant coagulopathy (with or without current therapeutic anticoagulation).\n* Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to treatment initiation.\n* Inadequately controlled hypertension (defined as systolic blood pressure (BP) >150 mmHg and/or diastolic blood pressure > 100 mmHg), an average of 3 BP readings on 2 sessions will be used to measure blood pressure if initial reading indicates inadequately controlled hypertension. NOTE: anti-hypertensive therapy to achieve blood pressures below these parameters is allowed.\n* Prior history of hypertensive crisis or hypertensive encephalopathy.\n* Persisting toxicity related to prior therapy of Grade >1 per Common Terminology Criteria for Adverse Events (CTCAE) v 5.0. NOTE: alopecia, sensory neuropathy Grade <=2 are acceptable.\n* Known active alcohol or drug abuse.\n* History of allergy to study drug components.\n* Pregnancy (confirmed with Beta-Human chorionic gonadotropin (Beta-HCG) serum or urine pregnancy test in WOCBP performed at screening).\n* Uncontrolled intercurrent illness or situation that would limit compliance with study requirements.\nHealthy volunteers allowed\nMust have minimum age of 18 Years\nMust have maximum age of 120 Years",
        "exclusion_criteria": "",
        "miscellaneous_criteria": ""
    },
    "inclusion_lines": [
        {
            "line": "* At least one of the following:",
            "criterions": [
                {
                    "exact_snippets": "At least one of the following",
                    "criterion": "at least one criterion from a list",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1,
                                "unit": "criterion"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Evidence of bleeding diathesis or significant coagulopathy (with or without current therapeutic anticoagulation).",
            "criterions": [
                {
                    "exact_snippets": "Evidence of bleeding diathesis",
                    "criterion": "bleeding diathesis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "significant coagulopathy (with or without current therapeutic anticoagulation)",
                    "criterion": "coagulopathy",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": "significant"
                        },
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Major surgery within 4 weeks prior to treatment initiation.",
            "criterions": [
                {
                    "exact_snippets": "Major surgery within 4 weeks prior to treatment initiation.",
                    "criterion": "major surgery",
                    "requirements": [
                        {
                            "requirement_type": "time since event",
                            "expected_value": {
                                "operator": ">=",
                                "value": 4,
                                "unit": "weeks"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* A history of 2 or more surgeries within 12 months prior to treatment initiation in order to control laryngeal and/or tracheal RRP (not required for re-treatment).",
            "criterions": [
                {
                    "exact_snippets": "A history of 2 or more surgeries within 12 months prior to treatment initiation in order to control laryngeal and/or tracheal RRP",
                    "criterion": "surgeries for laryngeal and/or tracheal RRP",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "surgeries"
                            }
                        },
                        {
                            "requirement_type": "time_window",
                            "expected_value": "within 12 months prior to treatment initiation"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Urinalysis: Urine dipstick < 2+ proteinuria. In participants with >=2+ proteinuria on dipstick urinalysis should undergo a 24-hour urine collection and must demonstrate <=1g of protein in 24 hours to be eligible",
            "criterions": [
                {
                    "exact_snippets": "Urine dipstick < 2+ proteinuria",
                    "criterion": "urine protein (dipstick)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 2,
                                "unit": "+"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "participants with >=2+ proteinuria on dipstick urinalysis should undergo a 24-hour urine collection and must demonstrate <=1g of protein in 24 hours",
                    "criterion": "urine protein (24-hour collection)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "g/24h"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prothrombin time (PT) /International normalized ratio (INR) and Partial thromboplastin time (PTT): <=1 X institutional ULN. In participants on anticoagulation, coagulation tests should be within a therapeutic range.",
            "criterions": [
                {
                    "exact_snippets": "Prothrombin time (PT) /International normalized ratio (INR) ... <=1 X institutional ULN",
                    "criterion": "prothrombin time (PT) / international normalized ratio (INR)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "institutional ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Partial thromboplastin time (PTT): <=1 X institutional ULN",
                    "criterion": "partial thromboplastin time (PTT)",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "institutional ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "participants on anticoagulation, coagulation tests should be within a therapeutic range",
                    "criterion": "coagulation tests in participants on anticoagulation",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": "within a therapeutic range"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* A Derkay score of 8 or greater",
            "criterions": [
                {
                    "exact_snippets": "A Derkay score of 8 or greater",
                    "criterion": "Derkay score",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 8,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Tracheostomy.",
            "criterions": [
                {
                    "exact_snippets": "Tracheostomy.",
                    "criterion": "tracheostomy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Breastfeeding participants must be willing to discontinue breastfeeding from study treatment initiation through 6 months after bevacizumab treatment discontinuation.",
            "criterions": [
                {
                    "exact_snippets": "Breastfeeding participants must be willing to discontinue breastfeeding from study treatment initiation through 6 months after bevacizumab treatment discontinuation.",
                    "criterion": "breastfeeding",
                    "requirements": [
                        {
                            "requirement_type": "status",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "willingness to discontinue",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "discontinuation period",
                            "expected_value": "from study treatment initiation through 6 months after bevacizumab treatment discontinuation"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Known active alcohol or drug abuse.",
            "criterions": [
                {
                    "exact_snippets": "Known active alcohol or drug abuse",
                    "criterion": "alcohol abuse",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Known active alcohol or drug abuse",
                    "criterion": "drug abuse",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* All participants must be willing to undergo mandatory biopsy during the study.",
            "criterions": [
                {
                    "exact_snippets": "willing to undergo mandatory biopsy during the study",
                    "criterion": "willingness to undergo biopsy",
                    "requirements": [
                        {
                            "requirement_type": "willingness",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "procedure",
                            "expected_value": "biopsy"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "during the study"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants must have adequate organ and marrow function as defined below:",
            "criterions": [
                {
                    "exact_snippets": "adequate organ and marrow function",
                    "criterion": "organ and marrow function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Creatinine Clearance (CrCl): >=60 mL/min/1.73 m^2 for participants with creatinine levels above institutional normal (calculated using the Cockcroft-Gault formula).",
            "criterions": [
                {
                    "exact_snippets": "Creatinine Clearance (CrCl): >=60 mL/min/1.73 m^2",
                    "criterion": "creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 60,
                                "unit": "mL/min/1.73 m^2"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "for participants with creatinine levels above institutional normal",
                    "criterion": "creatinine level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": "> institutional normal"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Non-healing wound, active ulcer, or untreated bone fracture.",
            "criterions": [
                {
                    "exact_snippets": "Non-healing wound",
                    "criterion": "wound",
                    "requirements": [
                        {
                            "requirement_type": "healing status",
                            "expected_value": "non-healing"
                        }
                    ]
                },
                {
                    "exact_snippets": "active ulcer",
                    "criterion": "ulcer",
                    "requirements": [
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        }
                    ]
                },
                {
                    "exact_snippets": "untreated bone fracture",
                    "criterion": "bone fracture",
                    "requirements": [
                        {
                            "requirement_type": "treatment status",
                            "expected_value": "untreated"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hemoglobin: >9.0 g/dL",
            "criterions": [
                {
                    "exact_snippets": "Hemoglobin: >9.0 g/dL",
                    "criterion": "hemoglobin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 9.0,
                                "unit": "g/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Creatinine: within normal institutional limits",
            "criterions": [
                {
                    "exact_snippets": "Creatinine: within normal institutional limits",
                    "criterion": "creatinine level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": "within normal institutional limits"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* All participants must have the ability to understand and willingness to sign a written informed consent.",
            "criterions": [
                {
                    "exact_snippets": "ability to understand",
                    "criterion": "cognitive ability",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "willingness to sign a written informed consent",
                    "criterion": "willingness to provide informed consent",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Total bilirubin: <=1.5 mg/dL, except in participants with Gilbert s Syndrome who must have a total bilirubin less than 3.0 mg/dL",
            "criterions": [
                {
                    "exact_snippets": "Total bilirubin: <=1.5 mg/dL",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1.5,
                                "unit": "mg/dL"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "except in participants with Gilbert s Syndrome who must have a total bilirubin less than 3.0 mg/dL",
                    "criterion": "total bilirubin in participants with Gilbert s Syndrome",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<",
                                "value": 3.0,
                                "unit": "mg/dL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants must have received their last systemic therapy for RRP > 4 weeks or 5 half-lives, whichever is longer, prior to treatment initiation, except for systemic bevacizumab which must be > 1 year prior to treatment initiation (not applicable for re-treatment)",
            "criterions": [
                {
                    "exact_snippets": "Participants must have received their last systemic therapy for RRP > 4 weeks or 5 half-lives, whichever is longer, prior to treatment initiation",
                    "criterion": "time since last systemic therapy for RRP",
                    "requirements": [
                        {
                            "requirement_type": "minimum duration since last therapy",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">",
                                        "value": 4,
                                        "unit": "weeks"
                                    },
                                    {
                                        "operator": ">",
                                        "value": 5,
                                        "unit": "half-lives"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "except for systemic bevacizumab which must be > 1 year prior to treatment initiation (not applicable for re-treatment)",
                    "criterion": "time since last systemic bevacizumab therapy",
                    "requirements": [
                        {
                            "requirement_type": "minimum duration since last bevacizumab",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "year"
                            }
                        },
                        {
                            "requirement_type": "applicability",
                            "expected_value": "not applicable for re-treatment"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Inadequately controlled hypertension (defined as systolic blood pressure (BP) >150 mmHg and/or diastolic blood pressure > 100 mmHg), an average of 3 BP readings on 2 sessions will be used to measure blood pressure if initial reading indicates inadequately controlled hypertension. NOTE: anti-hypertensive therapy to achieve blood pressures below these parameters is allowed.",
            "criterions": [
                {
                    "exact_snippets": "Inadequately controlled hypertension (defined as systolic blood pressure (BP) >150 mmHg and/or diastolic blood pressure > 100 mmHg)",
                    "criterion": "blood pressure",
                    "requirements": [
                        {
                            "requirement_type": "systolic blood pressure",
                            "expected_value": {
                                "operator": ">",
                                "value": 150,
                                "unit": "mmHg"
                            }
                        },
                        {
                            "requirement_type": "diastolic blood pressure",
                            "expected_value": {
                                "operator": ">",
                                "value": 100,
                                "unit": "mmHg"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "an average of 3 BP readings on 2 sessions will be used to measure blood pressure if initial reading indicates inadequately controlled hypertension",
                    "criterion": "blood pressure measurement method",
                    "requirements": [
                        {
                            "requirement_type": "measurement method",
                            "expected_value": "average of 3 BP readings on 2 sessions if initial reading is high"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Participants must require procedure(s) to remove papillomatous disease per standard of care.",
            "criterions": [
                {
                    "exact_snippets": "Participants must require procedure(s) to remove papillomatous disease",
                    "criterion": "requirement for procedure to remove papillomatous disease",
                    "requirements": [
                        {
                            "requirement_type": "necessity",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Histologically confirmed diagnosis of RRP.",
            "criterions": [
                {
                    "exact_snippets": "Histologically confirmed diagnosis of RRP",
                    "criterion": "recurrent respiratory papillomatosis (RRP) diagnosis",
                    "requirements": [
                        {
                            "requirement_type": "confirmation method",
                            "expected_value": "histologically confirmed"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have maximum age of 120 Years",
            "criterions": [
                {
                    "exact_snippets": "maximum age of 120 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "maximum",
                            "expected_value": {
                                "operator": "<=",
                                "value": 120,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* White blood cells (WBC): >2,000/microL",
            "criterions": [
                {
                    "exact_snippets": "White blood cells (WBC): >2,000/microL",
                    "criterion": "white blood cell count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">",
                                "value": 2000,
                                "unit": "microL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Age >= 18 years old.",
            "criterions": [
                {
                    "exact_snippets": "Age >= 18 years old",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of hemoptysis (>2.5 mL of bright red blood per episode) within 1 month prior to treatment initiation.",
            "criterions": [
                {
                    "exact_snippets": "History of hemoptysis (>2.5 mL of bright red blood per episode) within 1 month prior to treatment initiation.",
                    "criterion": "hemoptysis",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "volume_per_episode",
                            "expected_value": {
                                "operator": ">",
                                "value": 2.5,
                                "unit": "mL"
                            }
                        },
                        {
                            "requirement_type": "blood_color",
                            "expected_value": "bright red"
                        },
                        {
                            "requirement_type": "time_window",
                            "expected_value": {
                                "operator": "<=",
                                "value": 1,
                                "unit": "month prior to treatment initiation"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to treatment initiation.",
            "criterions": [
                {
                    "exact_snippets": "Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to treatment initiation.",
                    "criterion": "significant vascular disease",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to treatment initiation"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "aortic aneurysm requiring surgical repair",
                    "criterion": "aortic aneurysm requiring surgical repair",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to treatment initiation"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "recent peripheral arterial thrombosis",
                    "criterion": "peripheral arterial thrombosis",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "recency",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to treatment initiation"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ECOG performance status of 0-1.",
            "criterions": [
                {
                    "exact_snippets": "ECOG performance status of 0-1",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "value",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 0,
                                        "unit": "N/A"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 1,
                                        "unit": "N/A"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Tracheal involvement with RRP that has required two or more clinical interventions in the last 12 months (two or more clinical interventions not required for re-treatment)",
            "criterions": [
                {
                    "exact_snippets": "Tracheal involvement with RRP",
                    "criterion": "tracheal involvement with RRP",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "has required two or more clinical interventions in the last 12 months",
                    "criterion": "clinical interventions for tracheal RRP",
                    "requirements": [
                        {
                            "requirement_type": "number of interventions",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "interventions"
                            }
                        },
                        {
                            "requirement_type": "time period",
                            "expected_value": "last 12 months"
                        }
                    ]
                }
            ]
        },
        {
            "line": "-History of significant (i.e., active) cardiovascular disease or thromboembolic event:",
            "criterions": [
                {
                    "exact_snippets": "History of significant (i.e., active) cardiovascular disease",
                    "criterion": "cardiovascular disease",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "significance",
                            "expected_value": "significant"
                        },
                        {
                            "requirement_type": "activity_status",
                            "expected_value": "active"
                        }
                    ]
                },
                {
                    "exact_snippets": "History of significant (i.e., active) ... thromboembolic event",
                    "criterion": "thromboembolic event",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "significance",
                            "expected_value": "significant"
                        },
                        {
                            "requirement_type": "activity_status",
                            "expected_value": "active"
                        }
                    ]
                }
            ]
        },
        {
            "line": "cerebral vascular accident/stroke (within 6 months prior to treatment initiation), myocardial infarction (within 6 months prior to treatment initiation), unstable angina, congestive heart failure (>= New York Heart Association Classification Class II), or serious cardiac arrhythmia requiring medication as assessed by EKG.",
            "criterions": [
                {
                    "exact_snippets": "cerebral vascular accident/stroke (within 6 months prior to treatment initiation)",
                    "criterion": "cerebral vascular accident or stroke",
                    "requirements": [
                        {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to treatment initiation"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "myocardial infarction (within 6 months prior to treatment initiation)",
                    "criterion": "myocardial infarction",
                    "requirements": [
                        {
                            "requirement_type": "occurrence_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months prior to treatment initiation"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "unstable angina",
                    "criterion": "unstable angina",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "congestive heart failure (>= New York Heart Association Classification Class II)",
                    "criterion": "congestive heart failure",
                    "requirements": [
                        {
                            "requirement_type": "severity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 2,
                                "unit": "New York Heart Association Classification Class"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "serious cardiac arrhythmia requiring medication as assessed by EKG",
                    "criterion": "serious cardiac arrhythmia",
                    "requirements": [
                        {
                            "requirement_type": "requires_medication",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "assessment_method",
                            "expected_value": "EKG"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Aspartate aminotransferase (AST) /Alanine aminotransferase (ALT): <=2.5 X institutional upper limit of normal (ULN)",
            "criterions": [
                {
                    "exact_snippets": "Aspartate aminotransferase (AST) ... <=2.5 X institutional upper limit of normal (ULN)",
                    "criterion": "aspartate aminotransferase (AST) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Alanine aminotransferase (ALT): <=2.5 X institutional upper limit of normal (ULN)",
                    "criterion": "alanine aminotransferase (ALT) level",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2.5,
                                "unit": "x ULN"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Absolute neutrophil count (ANC): >=1,500/microL",
            "criterions": [
                {
                    "exact_snippets": "Absolute neutrophil count (ANC): >=1,500/microL",
                    "criterion": "absolute neutrophil count (ANC)",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 1500,
                                "unit": "microL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of abdominal fistula or gastrointestinal perforation within 6 months prior to treatment initiation.",
            "criterions": [
                {
                    "exact_snippets": "History of abdominal fistula ... within 6 months prior to treatment initiation.",
                    "criterion": "abdominal fistula",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "History of ... gastrointestinal perforation within 6 months prior to treatment initiation.",
                    "criterion": "gastrointestinal perforation",
                    "requirements": [
                        {
                            "requirement_type": "history_within_timeframe",
                            "expected_value": {
                                "operator": "<=",
                                "value": 6,
                                "unit": "months"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Platelets: >=100,000/microL",
            "criterions": [
                {
                    "exact_snippets": "Platelets: >=100,000/microL",
                    "criterion": "platelet count",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 100000,
                                "unit": "microL"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Uncontrolled intercurrent illness or situation that would limit compliance with study requirements.",
            "criterions": [
                {
                    "exact_snippets": "Uncontrolled intercurrent illness",
                    "criterion": "intercurrent illness",
                    "requirements": [
                        {
                            "requirement_type": "control status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                },
                {
                    "exact_snippets": "situation that would limit compliance with study requirements",
                    "criterion": "situation limiting compliance with study requirements",
                    "requirements": [
                        {
                            "requirement_type": "compliance limitation",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Pregnancy (confirmed with Beta-Human chorionic gonadotropin (Beta-HCG) serum or urine pregnancy test in WOCBP performed at screening).",
            "criterions": [
                {
                    "exact_snippets": "Pregnancy (confirmed with Beta-Human chorionic gonadotropin (Beta-HCG) serum or urine pregnancy test in WOCBP performed at screening)",
                    "criterion": "pregnancy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "confirmation_method",
                            "expected_value": [
                                "Beta-Human chorionic gonadotropin (Beta-HCG) serum pregnancy test",
                                "urine pregnancy test"
                            ]
                        },
                        {
                            "requirement_type": "population",
                            "expected_value": "women of childbearing potential (WOCBP)"
                        },
                        {
                            "requirement_type": "timing",
                            "expected_value": "at screening"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Persisting toxicity related to prior therapy of Grade >1 per Common Terminology Criteria for Adverse Events (CTCAE) v 5.0. NOTE: alopecia, sensory neuropathy Grade <=2 are acceptable.",
            "criterions": [
                {
                    "exact_snippets": "Persisting toxicity related to prior therapy of Grade >1 per Common Terminology Criteria for Adverse Events (CTCAE) v 5.0",
                    "criterion": "persisting toxicity related to prior therapy",
                    "requirements": [
                        {
                            "requirement_type": "severity grade",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "CTCAE v5.0"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "alopecia ... are acceptable",
                    "criterion": "alopecia",
                    "requirements": [
                        {
                            "requirement_type": "severity grade",
                            "expected_value": "any grade"
                        }
                    ]
                },
                {
                    "exact_snippets": "sensory neuropathy Grade <=2 are acceptable",
                    "criterion": "sensory neuropathy",
                    "requirements": [
                        {
                            "requirement_type": "severity grade",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "CTCAE v5.0"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior history of hypertensive crisis or hypertensive encephalopathy.",
            "criterions": [
                {
                    "exact_snippets": "Prior history of hypertensive crisis",
                    "criterion": "hypertensive crisis",
                    "requirements": [
                        {
                            "requirement_type": "prior history",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Prior history of ... hypertensive encephalopathy",
                    "criterion": "hypertensive encephalopathy",
                    "requirements": [
                        {
                            "requirement_type": "prior history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Measurable disease per RECIST 1.1 (participants with pulmonary RRP only)",
            "criterions": [
                {
                    "exact_snippets": "Measurable disease per RECIST 1.1",
                    "criterion": "disease measurability",
                    "requirements": [
                        {
                            "requirement_type": "measurability",
                            "expected_value": "per RECIST 1.1"
                        }
                    ]
                },
                {
                    "exact_snippets": "participants with pulmonary RRP only",
                    "criterion": "pulmonary RRP",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Individuals able to become pregnant and their partners must agree to use highly effective method of contraception (hormonal, intrauterine device (IUD), surgical sterilization ) for the duration of bevacizumab treatment and up to 6 months after completion of bevacizumab treatment. Note: abstinence, defined as no heterosexual sexual intercourse when this is in line with the preferred and usual lifestyle of the participant is also acceptable.",
            "criterions": [
                {
                    "exact_snippets": "Individuals able to become pregnant and their partners must agree to use highly effective method of contraception (hormonal, intrauterine device (IUD), surgical sterilization ) for the duration of bevacizumab treatment and up to 6 months after completion of bevacizumab treatment.",
                    "criterion": "contraception use",
                    "requirements": [
                        {
                            "requirement_type": "method",
                            "expected_value": [
                                "hormonal",
                                "intrauterine device (IUD)",
                                "surgical sterilization"
                            ]
                        },
                        {
                            "requirement_type": "duration",
                            "expected_value": "for the duration of bevacizumab treatment and up to 6 months after completion of bevacizumab treatment"
                        }
                    ]
                },
                {
                    "exact_snippets": "abstinence, defined as no heterosexual sexual intercourse when this is in line with the preferred and usual lifestyle of the participant is also acceptable.",
                    "criterion": "sexual abstinence",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "definition",
                            "expected_value": "no heterosexual sexual intercourse when this is in line with the preferred and usual lifestyle of the participant"
                        }
                    ]
                }
            ]
        },
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of allergy to study drug components.",
            "criterions": [
                {
                    "exact_snippets": "History of allergy to study drug components",
                    "criterion": "allergy to study drug components",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [],
    "miscellaneous_lines": [],
    "failed_inclusion": [
        {
            "line": "OR",
            "criterions": []
        },
        {
            "line": "* INCLUSION CRITERIA:",
            "criterions": []
        },
        {
            "line": "EXCLUSION CRITERIA:",
            "criterions": []
        }
    ],
    "failed_exclusion": [],
    "failed_miscellaneous": []
}